Compare Amgen, Inc. (AMGN) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Kohl's Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Kohl's Corporation trades at $16.8 (market cap $1.91B). The key difference: Amgen, Inc. is far larger — about 102.7× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| AMGN | KSS | |
|---|---|---|
Market Cap | $196.12B | $1.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $24.71 |
52-Week Low | $271.18 | $9.27 |
Enterprise Value | $241.41B | $8.01B |
Dividend Yield | 2.77% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Kohl's (KSS) trades at $16.80, up 3.0% today, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten expectations, with Q1 2026 showing early turnaround progress, but revenue has declined from $19.4B in 2022 to $16.2B in 2025. The stock is undervalued with a P/E of 7.06 and P/B of 0.47, while analyst sentiment is cautious with a consensus price target of $16.75.
The outlook hinges on Kohl's ability to stabilize sales through proprietary brands and cost controls, but risks include persistent revenue declines and competitive pressures. Upside potential exists if turnaround efforts gain traction, yet investor caution is warranted given weak technicals and mixed analyst ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
